Search

In 2004, all national universities in Japan, which had previously been legally subordinate to the Ministry of Education, Culture, Sports, Science and Technology (MEXT), became separate National University Corporations. With this change, the importance of securing competitive funding increased significantly, and university researchers have had to devote more time to non-research burdens related to obtaining competitive funds including project management and public engagement. In order to reduce the burden for researchers in Japan, MEXT launched a support program in 2011 called the "System to Develop and Secure University Research Administrators (URA)." Supported by the program, Kyoto University established The Kyoto University Research Administration Office (KURA) in April 2012 as a support organization to help with planning of research projects, obtaining research funding, project execution, and public engagement. In this article, the strategic planning to implement the URA program at Kyoto University shall be described within the historical context of how the Japanese government decided to launch this support initiative.

An object viewed from different angles can be recognized and distinguished from similar distractors after the viewer has had experience watching it rotate. It has been assumed that as an observer watches the rotation, separate representations of individual views become associated with one another. However, we show here that once monkeys learned to discriminate individual views of objects, they were able to recognize objects across rotations up to 60°, even though there had been no opportunity to learn the association between different views. Our results suggest that object recognition across small or medium changes in viewing angle depends on features common to similar views of objects. [ABSTRACT FROM AUTHOR]

Since 1993, the"R & D Promotion System for Orphan Drugs and Orphan Medical Devices"has been in operation to support the development of orphan drugs in Japan. Various supportive measures are in place for indications that target less than 50,000 patients, have high medical needs and high probability of successful development(which means regulatory approval). However, recently a trend was observed that the designation for orphan drugs occurred most often in late phase of development, because clinical data for late stage clinical studies were required to show the high probability of successful regulatory approval. The Ministry of Health, Labour and Welfare are trying to make efforts to expand the orphan drug designation, and have made the decision to include the related expenses will be included in the FY 2023 budget request. It is expected that the expansion of orphan drug designation will lead to promote drug development in rare disease area. On the other hand, fundamental reform is considered necessary for this system. Among the approved anti-cancer drugs that obtained orphan designation in the U. S. and EU as of 2020, there are 24 drugs that have not been approved in Japan. Of these, there are at least 16 drugs approved in either China, Taiwan, and South Korea. From viewpoint of development pathway of an orphan drug, participation in a multi-regional clinical trial(MRCT)is useful, but there are cases that Japan cannot join MRCT in time due to the requirement of Japanese safety data prior to the participation. In that case, it is impossible to conduct a separate clinical trial to obtain Japan regulatory approval due to very limited patients(eg several to several tens of Ultra-Orphan). A review system that allows earlier patient access is desired.